LAUREN DEAL: Open Payments
NPI 1932824307 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,340 in 65 payments from 17 companies in 2025. Trend: 2023 $365 · 2024 $638 · 2025 $1,340
Food & beverage: $1,340
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 10 | $205 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $158 |
| Axsome Therapeutics, Inc. | 7 | $144 |
| ABBVIE INC. | 5 | $103 |
| Supernus Pharmaceuticals, Inc. | 5 | $102 |
| Alkermes, Inc. | 5 | $102 |
| Vanda Pharmaceuticals Inc. | 3 | $88 |
| Neurocrine BioSciences, Inc. | 4 | $87 |
| E.R. Squibb & Sons, L.L.C. | 3 | $71 |
| IDORSIA PHARMACEUTICALS US INC | 3 | $65 |
Products named: CAPLYTA, Auvelity, UZEDY, VRAYLAR, Qelbree, ARISTADA, REXULTI, INGREZZA.
Industry payments across MD — which companies pay providers there.
